Cecilia Klein, PhD
Director for Discovery and Translational Science Consulting
As Global Lead for Clarivate Discovery and Translational Science Consulting Services, Cecilia leads a team of consultants with in-depth knowledge in statistical and machine learning techniques, network, image and multi-OMICs data analysis. They support pharma and biotech customers in the drug discovery process through target and biomarker identification, understanding mechanisms of pathology or drug action and prioritizing candidates for drug repurposing.
Cecilia is expert at making the complex simple and actionable in a timely manner. Her focus is on helping scientists improve decision making and accelerate execution in the area of drug discovery.
Over the past 10+ years working as a computational biologist, she has dealt with virtually every flavor of NGS technologies at every stage of the experimental process: from experimental design through data acquisition to analysis, visualization and interpretation of the results.
Prior to joining Clarivate in 2019, Cecilia completed her PhD in Bioinformatics at the University of Lyon (France) and her Masters in Computational Biology at the National Laboratory of Scientific Computing (Rio de Janeiro, Brazil). She received her Bachelors Degree in Biology from the Federal University of Rio Grande do Sul. She speaks five languages: Portuguese, Spanish, French, English and Catalan. She is also learning Japanese.
Latest news
Clarivate’s IPfolio and Renewal Services Selected by IGT
Managing global intellectual property more efficiently with trusted data, expert support and integrated services London, U.K. May 21, 2026: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today…
Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform
New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility London, U.K. May 19, 2026: Clarivate Plc (NYSE:CLVT), a…
